Top

Published in:

01-03-2020 | Pedodontics

Oral and dental considerations in pediatric cancers

Authors: Priyanshi Ritwik, Tammuella E. Chrisentery-Singleton

Published in: Cancer and Metastasis Reviews | Issue 1/2020

Abstract

Oral health care is an integral component of interprofessional collaborative care for children and adolescents diagnosed with cancer. The current review highlights the phases of cancer therapy when dental interventions and palliative care are necessary for children diagnosed with cancer. Contemporary research and review articles pertinent to the oral and dental complications during pediatric cancer therapy and late effects in pediatric cancer survivors were identified by PubMed/MEDLINE search. Best practice guidelines set forth by specialty organizations were also included. The literature search was limited to articles published in the English language. Baseline oral and dental health assessment should occur before initiation of cancer therapy to prevent debilitating complications during the immunosuppressed phase. Counseling on preventive oral health practices is imperative during cancer treatment. Ideally, all dental treatment should be completed before initiation of immunosuppressive therapy. Palliative care and treatment for mucositis, opportunistic oral infections, pain, and other oral complications associated with cancer therapy should be provided as necessary. Survivors of childhood cancers present with unique craniofacial and dental anomalies, dependent on the type of cancer treatment and age at the time of treatment. Pediatric dentists and pediatric oncology teams work collaboratively to screen for and treat dental and oral diseases. As the survival rates of childhood cancers improve, it is essential for the dental profession to provide the individualized care necessary for this vulnerable population. The oral health profession also reinforces health practices congruent with cancer prevention and cancer screening.

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7–30. https://doi.org/10.3322/caac.21442.CrossRef

Noone, A. M., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D. R., Chen, H. S., Feuer, E. J., Cronin, K. A. SEER cancer statistics review, 1975–2015, national cancer institute. Bethesda, MD, based on November 2017 SEER data submission. https://seer.cancer.gov/csr/1975_2015/. Updated 2018. Accessed -4-19, 11.

Jemal, A., Ward, E. M., Johnson, C. J., et al. (2017). Annual report to the nation on the status of cancer, 1975–2014, featuring survival. Journal of the National Cancer Institute, 109(9). https://doi.org/10.1093/jnci/djx030.

Curtin, S. C., Minino, A. M., & Anderson, R. N. (2016). Declines in cancer death rates among children and adolescents in the United States, 1999–2014. NCHS Data Brief, (257), 1–8.

Childhood cancer rates calculated using the incidence SEER18 research database, November 2017 submission (Katrina/Rita population adjustment). All cancer site rates are based on the SEER site codes with the exception of medulloblastoma, which used site code C71.6 and international classification code of diseases for oncology, third edition (ICD-O-3) malignant histologic codes 9470/3, 9471/3, and 9474/3.

Ross, J. A., Spector, L. G., Robison, L. L., & Olshan, A. F. (2005). Epidemiology of leukemia in children with down syndrome. Pediatric Blood & Cancer, 44(1), 8–12. https://doi.org/10.1002/pbc.20165.CrossRef

Lu, C., Zhang, J., Nagahawatte, P., Easton, J., Lee, S., Liu, Z., Ding, L., Wyczalkowski, M. A., Valentine, M., Navid, F., Mulder, H., Tatevossian, R. G., Dalton, J., Davenport, J., Yin, Z., Edmonson, M., Rusch, M., Wu, G., Li, Y., Parker, M., Hedlund, E., Shurtleff, S., Raimondi, S., Bhavin, V., Donald, Y., Mardis, E. R., Wilson, R. K., Evans, W. E., Ellison, D. W., Pounds, S., Dyer, M., Downing, J. R., Pappo, A., & Bahrami, A. (2015). The genomic landscape of childhood and adolescent melanoma. The Journal of Investigative Dermatology, 135(3), 816–823.CrossRefPubMed

Hsu, W. L., Preston, D. L., Soda, M., et al. (2013). The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950–2001. Radiation Research, 179(3), 361–382. https://doi.org/10.1667/RR2892.1.CrossRefPubMed

Pearce, M. S., Salotti, J. A., Little, M. P., et al. (2012). Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: A retrospective cohort study. Lancet, 380(9840), 499–505. https://doi.org/10.1016/S0140-6736(12)60815-0.CrossRefPubMedPubMedCentral

10.

Biggar, R. J., Frisch, M., & Goedert, J. J. (2000). Risk of cancer in children with AIDS. AIDS-cancer match registry study group. JAMA., 284(2), 205–209.CrossRefPubMed

11.

Sorahan, T., McKinney, P. A., Mann, J. R., et al. (2001). Childhood cancer and parental use of tobacco: Findings from the inter-regional epidemiological study of childhood cancer (IRESCC). British Journal of Cancer, 84(1), 141–146. https://doi.org/10.1054/bjoc.2000.1556.CrossRefPubMedPubMedCentral

12.

Chen, M., Chang, C. H., Tao, L., & Lu, C. (2015). Residential exposure to pesticide during childhood and childhood cancers: A meta-analysis. Pediatrics, 136(4), 719–729. https://doi.org/10.1542/peds.2015-0006.CrossRefPubMed

13.

Adamson, P., Arons, D., Baumberger, J., Fluery, M., Hoffman, R., Leach, D., & Weiner, S. (2016). Translating discovery into cures for children with cancer childhood cancer research landscape report. Alliance for Childhood Cancer and American Cancer Society, 1–88.

14.

Hord, J. F. S. (2014). Policy statement: Standards for pediatric cancer centers. Pediatrics., 134, 410–414.CrossRef

15.

Jiles, C., Wu, E., Bernhardt, M. B., & Kamalay, S. (2018). Pediatric cancer treatment development. PedSAP 2018 book 1 • pediatric oncology 25. American College of Clinical Pharmacology.

16.

Pui, C. H., Pei, D., Sandlund, J. T., et al. (2010). Long-term results of St. Jude total therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia, 24(2), 371–382. https://doi.org/10.1038/leu.2009.252.CrossRefPubMed

17.

Hewitt, M., Weiner, S. L., & Simone, J. V. (2003). Childhood Cancer Survivorship. In Childhood cancer survivorship: Improving care and quality of life. Washington (DC): Institute of Medicine (US) and National Research Council (US) National Cancer Policy Board; National Academies Press (US).

18.

Ram, R., Wolach, O., Vidal, L., Gafter-Gvili, A., Shpilberg, O., & Raanani, P. (2012). Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: Systematic review and meta-analysis. American Journal of Hematology, 87(5), 472–478.CrossRefPubMed

19.

Barr, R. D., Ries, L. A., Lewis, D. R., et al. (2016). Incidence and incidence trends of the most frequent cancers in adolescent and young adult Americans, including "nonmalignant/noninvasive" tumors. Cancer, 122(7), 1000–1008. https://doi.org/10.1002/cncr.29867.CrossRefPubMed

20.

Oeffinger, K. C., Mertens, A. C., Sklar, C. A., et al. (2006). Chronic health conditions in adult survivors of childhood cancer. The New England Journal of Medicine, 355(15), 1572–1582.CrossRefPubMed

21.

Meadows, A. T., Friedman, D. L., Neglia, J. P., et al. (2009). Second neoplasms in survivors of childhood cancer: Findings from the childhood cancer survivor study cohort. Journal of Clinical Oncology, 27(14), 2356–2362. https://doi.org/10.1200/JCO.2008.21.1920.CrossRefPubMedPubMedCentral

22.

Armstrong, G. T., Kawashima, T., Leisenring, W., et al. (2014). Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. Journal of Clinical Oncology, 32(12), 1218–1227. https://doi.org/10.1200/JCO.2013.51.1055.CrossRefPubMedPubMedCentral

23.

Armstrong, G. T., Chen, Y., Yasui, Y., et al. (2016). Reduction in late mortality among 5-year survivors of childhood cancer. The New England Journal of Medicine, 374(9), 833–842. https://doi.org/10.1056/NEJMoa1510795.CrossRefPubMedPubMedCentral

24.

(2018). Dental management of pediatric patients receiving immunosuppressive therapy and/or radiation therapy. Pediatric Dentistry, 40, 392–400.

25.

Ritwik, P. (2018). Dental care for patients with childhood cancers. The Ochsner Journal, 18(4), 351–357. https://doi.org/10.31486/toj.18.0061.CrossRefPubMedPubMedCentral

26.

Hong, C. H., & daFonseca, M. (2008). Considerations in the pediatric population with cancer. Dental Clinics of North America, 52(1), 155–81, ix.CrossRefPubMed

27.

McGill, B. C., Wakefield, C., Vetsch, J., Lim, Q., Warby, M., Metcalfe, A., Byrne, J. A., Cohn, R. J., & Tucker, K. M. (2019). “I remember how I felt, but I don't remember the gene”: Families' experiences of cancer-related genetic testing in childhood. Pediatric Blood & Cancer, 66(8), e27762.CrossRef

28.

Landier, W., & Tse, A. M. (2010). Use of complementary and alternative medical interventions for the management of procedure-related pain, anxiety, and distress in pediatric oncology: An integrative review. Journal of Pediatric Nursing, 25(6), 566–579. https://doi.org/10.1016/j.pedn.2010.01.009.CrossRefPubMedPubMedCentral

29.

(2017). Policy on early childhood caries (ECC): Classifications, consequences, and preventive strategies. Pediatric Dentistry, 39(6), 59–61.

30.

Clarkson, J. E., & Eden, O. B. (1998). Dental health in children with cancer. Archives of Disease in Childhood, 78(6), 560–561. https://doi.org/10.1136/adc.78.6.560.CrossRefPubMedPubMedCentral

31.

Hartnett, E., & Krainovich-Miller, B. (2017). Preventive dental care: An educational program to integrate oral care into pediatric oncology. Clinical Journal of Oncology Nursing, 21(5), 611–616. https://doi.org/10.1188/17.CJON.611-616.CrossRefPubMed

32.

Cubukcu, C. E., & Gunes, A. M. (2008). Caries experience of leukemic children during intensive course of chemotherapy. The Journal of Clinical Pediatric Dentistry, 32(2), 155–158.CrossRefPubMed

33.

(2016). Guideline on fluoride therapy. Pediatric Dentistry, 38(6), 181–184.

34.

(2016). Guideline on caries-risk assessment and management for infants, children, and adolescents. Pediatric Dentistry, 38(6), 142–149.

35.

Llena, C., Forner, L., & Baca, P. (2009). Anticariogenicity of casein phosphopeptide-amorphous calcium phosphate: A review of the literature. The Journal of Contemporary Dental Practice, 10(3), 1–9.CrossRefPubMed

36.

Katz, J., & Peretz, B. (2002). Trismus in a 6 year old child: A manifestation of leukemia? The Journal of Clinical Pediatric Dentistry, 26(4), 337–339.CrossRefPubMed

37.

Rapidis, A. D., Dijkstra, P. U., Roodenburg, J. L., et al. (2015). Trismus in patients with head and neck cancer: Etiopathogenesis, diagnosis and management. Clinical Otolaryngology, 40(6), 516–526. https://doi.org/10.1111/coa.12488.CrossRefPubMed

38.

Wang, C. J., Huang, E. Y., Hsu, H. C., Chen, H. C., Fang, F. M., & Hsiung, C. Y. (2005). The degree and time-course assessment of radiation-induced trismus occurring after radiotherapy for nasopharyngeal cancer. Laryngoscope., 115(8), 1458–1460.CrossRefPubMed

39.

Slayton, R. L., Urquhart, O., Araujo, M. W. B., et al. (2018). Evidence-based clinical practice guideline on nonrestorative treatments for carious lesions: A report from the American dental association. Journal of the American Dental Association (1939), 149(10), 837–849.e19.CrossRef

40.

(2017). Use of silver diamine fluoride for dental caries management in children and adolescents, including those with special health care needs. Pediatric Dentistry, 39(6), 146–155.

41.

Sheller, B., & Williams, B. (1996). Orthodontic management of patients with hematologic malignancies. American Journal of Orthodontics and Dentofacial Orthopedics, 109(6), 575–580.CrossRefPubMed

42.

Dahllof, G., Jonsson, A., Ulmner, M., & Huggare, J. (2001). Orthodontic treatment in long-term survivors after pediatric bone marrow transplantation. American Journal of Orthodontics and Dentofacial Orthopedics, 120(5), 459–465.CrossRefPubMed

43.

Chockattu, S. J., Suryakant, D. B., & Thakur, S. (2018). Unwanted effects due to interactions between dental materials and magnetic resonance imaging: A review of the literature. Restorative Dentistry & Endodontics, 43(4), e39. https://doi.org/10.5395/rde.2018.43.e39.CrossRef

44.

Curra, M., Soares Junior, L. A. V., Martins, M. D., & Santos, P. S. D. S. (2018). Chemotherapy protocols and incidence of oral mucositis. An integrative review. Einstein (Sao Paulo), 16(1), eRW4007–45082018rw4007.CrossRef

45.

Maria, O. M., Eliopoulos, N., & Muanza, T. (2017). Radiation-induced oral mucositis. Frontiers in Oncology, 7, 89. https://doi.org/10.3389/fonc.2017.00089.CrossRefPubMedPubMedCentral

46.

Staudenmaier, T., Cenzer, I., Crispin, A., Ostermann, H., & Berger, K. (2018). Burden of oral mucositis in stem cell transplant patients-the patients' perspective. Support Care Cancer, 26(5), 1577–1584. https://doi.org/10.1007/s00520-017-4000-5.CrossRefPubMed

47.

Peterson, D. E., Bensadoun, R. J., Roila, F., & ESMO Guidelines Working Group. (2011). Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Annals of Oncology, 22(Suppl 6), vi78–vi84. https://doi.org/10.1093/annonc/mdr391.CrossRefPubMedPubMedCentral

48.

Proc, P., Szczepanska, J., Herud, A., Zubowska, M., Fendler, W., & Mlynarski, W. (2019). Dental caries among childhood cancer survivors. Medicine (Baltimore), 98(6), e14279. https://doi.org/10.1097/MD.0000000000014279.CrossRef

49.

Glenny, A. M., Gibson, F., Auld, E., et al. (2010). The development of evidence-based guidelines on mouth care for children, teenagers and young adults treated for cancer. European Journal of Cancer, 46(8), 1399–1412. https://doi.org/10.1016/j.ejca.2010.01.023.CrossRefPubMed

50.

Velten, D. B., Zandonade, E., & Monteiro de Barros Miotto, M. H. (2017). Prevalence of oral manifestations in children and adolescents with cancer submitted to chemotherapy. BMC Oral Health, 17(1), 49–48. https://doi.org/10.1186/s12903-016-0331-8.CrossRefPubMedPubMedCentral

51.

Morgan, J. E., Hassan, H., Cockle, J. V., Lethaby, C., James, B., & Phillips, R. S. (2017). Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology. Support Care Cancer, 25(1), 221–228. https://doi.org/10.1007/s00520-016-3412-y.CrossRefPubMed

52.

Ponce-Torres, E., Ruiz-Rodriguez Mdel, S., Alejo-Gonzalez, F., Hernandez-Sierra, J. F., & Pozos-Guillen, A. J. (2010). Oral manifestations in pediatric patients receiving chemotherapy for acute lymphoblastic leukemia. The Journal of Clinical Pediatric Dentistry, 34(3), 275–279.CrossRefPubMed

53.

Fleming, P. (1991). Dental management of the pediatric oncology patient. Current Opinion in Dentistry, 1(5), 577–582.PubMed

54.

Effinger, K. E., Migliorati, C. A., Hudson, M. M., et al. (2014). Oral and dental late effects in survivors of childhood cancer: A children's oncology group report. Support Care Cancer, 22(7), 2009–2019. https://doi.org/10.1007/s00520-014-2260-x.CrossRefPubMedPubMedCentral

55.

Kang, C. M., Hahn, S. M., Kim, H. S., et al. (2018). Clinical risk factors influencing dental developmental disturbances in childhood cancer survivors. Cancer Research and Treatment, 50(3), 926–935. https://doi.org/10.4143/crt.2017.296.CrossRefPubMed

56.

King, E. (2019). Oral sequelae and rehabilitation considerations for survivors of childhood cancer. British Dental Journal, 226(5), 323–329. https://doi.org/10.1038/s41415-019-0043-y.CrossRefPubMed

57.

Lauritano, D., & Petruzzi, M. (2012). Decayed, missing and filled teeth index and dental anomalies in long-term survivors leukaemic children: A prospective controlled study. Medicina Oral, Patología Oral y Cirugía Bucal, 17(6), 977.CrossRef

58.

Avsar, A., Elli, M., Darka, O., & Pinarli, G. (2007). Long-term effects of chemotherapy on caries formation, dental development, and salivary factors in childhood cancer survivors. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 104(6), 781–789.CrossRefPubMed

59.

Nemeth, O., Hermann, P., Kivovics, P., & Garami, M. (2013). Long-term effects of chemotherapy on dental status of children cancer survivors. Pediatric Hematology and Oncology, 30(3), 208–215. https://doi.org/10.3109/08880018.2013.763391.CrossRefPubMed

60.

Wilberg, P., Kanellopoulos, A., Ruud, E., Hjermstad, M. J., Fossa, S. D., & Herlofson, B. B. (2016). Dental abnormalities after chemotherapy in long-term survivors of childhood acute lymphoblastic leukemia 7–40 years after diagnosis. Support Care Cancer, 24(4), 1497–1506. https://doi.org/10.1007/s00520-015-2940-1.CrossRefPubMed

61.

Bagattoni, S., D'Alessandro, G., Prete, A., Piana, G., & Pession, A. (2014). Oral health and dental late adverse effects in children in remission from malignant disease. A pilot case-control study in Italian children. European Journal of Paediatric Dentistry, 15(1), 45–50.CrossRefPubMed

62.

Carpenter, P. A., & Macmillan, M. L. (2010). Management of acute graft-versus-host disease in children. Pediatric Clinics of North America, 57(1), 273–295. https://doi.org/10.1016/j.pcl.2009.11.007.CrossRefPubMedPubMedCentral

63.

Baird, K., Cooke, K., & Schultz, K. R. (2010). Chronic graft-versus-host disease (GVHD) in children. Pediatric Clinics of North America, 57(1), 297–322. https://doi.org/10.1016/j.pcl.2009.11.003.CrossRefPubMedPubMedCentral

64.

Sheedy, T., & Heaton, C. (2019). HPV-associated oropharyngeal cancer. JAAPA, 32(9), 26–31. https://doi.org/10.1097/01.JAA.0000578756.52642.cb.CrossRefPubMed

65.

Kreimer, A. R., Clifford, G. M., Boyle, P., & Franceschi, S. (2005). Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiology, Biomarkers and Prevention, 14(2), 467–475.CrossRefPubMed

66.

Yete, S., D'Souza, W., & Saranath, D. (2018). High-risk human papillomavirus in oral cancer: Clinical implications. Oncology, 94(3), 133–141. https://doi.org/10.1159/000485322.CrossRefPubMed

67.

ADA policy on HPV vaccination. https://www.ada.org/en/member-center/oral-health-topics/cancer-head-and-neck#. Updated 2019. Accessed 10–28-19.

68.

(2018). Policy on human papilloma virus vaccinations. Pediatric Dentistry, 40(6), 82–83.

69.

HPV vaccine is cancer prevention. https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/immunizations/HPV-Champion-Toolkit/Pages/Whats-New-with-HPV-Vaccine.aspx. Updated 2019. Accessed 10–28-19.

70.

CDC HPV vaccine schedule and dosing. https://www.cdc.gov/hpv/hcp/schedules-recommendations.html. Updated 2019. Accessed 10–28-19.

71.

Yardimci, G., Kutlubay, Z., Engin, B., & Tuzun, Y. (2014). Precancerous lesions of oral mucosa. World Journal of Clinical Cases, 2(12), 866–872. https://doi.org/10.12998/wjcc.v2.i12.866.CrossRefPubMedPubMedCentral

72.

Boukheris, H., Stovall, M., Gilbert, E. S., et al. (2013). Risk of salivary gland cancer after childhood cancer: A report from the childhood cancer survivor study. International Journal of Radiation Oncology, Biology, Physics, 85(3), 776–783. https://doi.org/10.1016/j.ijrobp.2012.06.006.CrossRefPubMed

73.

Kirac, D., Eraydin, F., Avcilar, T., et al. (2016). Effects of PAX9 and MSX1 gene variants to hypodontia, tooth size and the type of congenitally missing teeth. Cellular and Molecular Biology (Noisy-le-Grand, France), 62(13), 78–84. https://doi.org/10.14715/cmb/2016.62.13.14.CrossRef

74.

Ritwik, P., & Patterson, K. K. (2018). Diagnosis of tooth agenesis in childhood and risk for neoplasms in adulthood. The Ochsner Journal, 18(4), 345–350. https://doi.org/10.31486/toj.18.0060.CrossRefPubMedPubMedCentral

75.

Yin, W., & Bian, Z. (2015). The gene network underlying hypodontia. Journal of Dental Research, 94(7), 878–885. https://doi.org/10.1177/0022034515583999.CrossRefPubMed

76.

Yin, W., & Bian, Z. (2016). Hypodontia, a prospective predictive marker for tumor? Oral Diseases, 22(4), 265–273. https://doi.org/10.1111/odi.12400.CrossRefPubMed

77.

Williams, M. A., Biguetti, C., Romero-Bustillos, M., et al. (2018). Colorectal cancer-associated genes are associated with tooth agenesis and may have a role in tooth development. Scientific Reports, 8(1), 2979–z. https://doi.org/10.1038/s41598-018-21368-z.CrossRef

78.

Tan, B., Wang, J., Song, Q., et al. (2017). Prognostic value of PAX9 in patients with esophageal squamous cell carcinoma and its prediction value to radiation sensitivity. Molecular Medicine Reports, 16(1), 806–816. https://doi.org/10.3892/mmr.2017.6626.CrossRefPubMedPubMedCentral

79.

Juuri, E., & Balic, A. (2017). The biology underlying abnormalities of tooth number in humans. Journal of Dental Research, 96(11), 1248–1256. https://doi.org/10.1177/0022034517720158.CrossRefPubMed

80.

Lammi, L., Arte, S., Somer, M., et al. (2004). Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. American Journal of Human Genetics, 74(5), 1043–1050. https://doi.org/10.1086/386293.CrossRefPubMedPubMedCentral

81.

Chalothorn, L. A., Beeman, C. S., Ebersole, J. L., Kluemper, G. T., Hicks, E. P., Kryscio, R. J., DeSimone, C., & Modesitt, S. C. (2008). Hypodontia as a risk marker for epithelial ovarian cancer: A case-controlled study. Journal of the American Dental Association (1939), 139(2), 163–169.CrossRef

82.

Fekonja, A., Cretnik, A., Zerdoner, D., & Takac, I. (2015). Hypodontia phenotype in patients with epithelial ovarian cancer. Radiology and Oncology, 49(1), 65–70. https://doi.org/10.2478/raon-2014-0034.CrossRefPubMedPubMedCentral

83.

Marvin, M. L., Mazzoni, S. M., Herron, C. M., Edwards, S., Gruber, S. B., & Petty, E. M. (2011). AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. American Journal of Medical Genetics. Part A, 155A(4), 898–902. https://doi.org/10.1002/ajmg.a.33927.CrossRefPubMed

84.

Kuchler, E. C., Lips, A., Tannure, P. N., et al. (2013). Tooth agenesis association with self-reported family history of cancer. Journal of Dental Research, 92(2), 149–155. https://doi.org/10.1177/0022034512468750.CrossRefPubMed

Title: Oral and dental considerations in pediatric cancers
Authors: Priyanshi Ritwik
Tammuella E. Chrisentery-Singleton
Publication date: 01-03-2020
Publisher: Springer US
Keywords: Pedodontics
Pedodontics
Pediatric Cancer
Cancer Therapy
Caries
Published in: Cancer and Metastasis Reviews / Issue 1/2020
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-020-09842-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Clinical research tools in pediatric oncology: challenges and opportunities

Professor Samuel C. Brooks, Jr., Ph.D. (1928–2019)

Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data

A systematic approach to the endocrine care of survivors of pediatric hematopoietic stem cell transplantation

Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches

Signaling pathways in Rhabdomyosarcoma invasion and metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer